🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

+++ #NEWS +++ Bayer starts Phase II clinical study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumors. Read more here: bayer.com/media/en-us/

40% of people with diabetes will develop #ChronicKidneyDisease. Over half of them are likely to know nothing about #CKD before diagnosis. This World Kidney Day, let’s raise awareness & commit to educating communities about #CKD. Early detection is key to protecting #KidneyHealth.

#NEWS: U.S. FDA grants Priority Review to a new therapy for adult patients with common form of heart failure. Learn more: bayer.com/media/en-us/

For Investors & Medical Media. From March 19–22, 2025, Bayer will be at the 16th Congress of the European Society of Gynecology to deliver presentations encompassing a multiple of symptoms associated with menopause. Learn more here 👇 bayer.com/media/en-us/

#News: Together with Puhe BioPharma, we’ve launched a phase I study targeting tumors lacking the MTAP gene. This innovative approach may offer new hope for patients facing hard-to-treat cancers. Learn more: bayer.com/media/ #TeamBayer

Bayer is revolutionizing healthcare in oncology, cardiovascular diseases, women’s health and more through R&D and innovative programs addressing the world’s greatest unmet medical needs. #PharmaMediaDay #PMD25 #TeamBayer

#News: Together with Vividion Therapeutics, we have initiated a Phase I trial, targeting RAS-driven cancers. This innovative approach could provide new treatment options for patients facing challenging cancers. Learn more: bayer.com/media/ #TeamBayer

#News: Together with Vividion Therapeutics, we have initiated a Phase I trial, targeting RAS-driven cancers. This innovative approach could provide new treatment options for patients facing challenging cancers. Learn more: bayer.com/media/ #TeamBayer #PrecisionOncology

At Pharma Media Day 2025, we showcased the latest advancements in oncology, cardiovascular care, women’s health and more, highlighting our commitment to R&D and commercial excellence. Check out some of our highlights! #TeamBayer #PharmaMediaDay #PMD25

#NEWS: Bayer files for EU approval of eye drug with long dosing intervals for the treatment of retinal vein occlusion. Learn more: bayer.com/media/en-us/

+++#NEWS+++ #TeamBayer & Vividion Therapeutics are set to present innovative oncology research data at #AACR2025. Together we advance new treatments opportunities targeting cancers. Learn more: bayer.com/media/en-us/

The 11th Annual Society of Endometriosis and Uterine Disorders (SEUD) Congress has officially begun! Bayer is excited to connect with the global healthcare community and exchange insights on improving women’s health.

+++#NEWS+++ #TeamBayer presents latest research at #ARVO2025. We will share early real-world data from a global study in patients with wet age-related macular degeneration and diabetic macular edema.

#TeamBayer has launched a Phase I trial for a targeted alpha radiopharmaceutical designed to treat advanced hepatocellular carcinoma. With this, we aim to improve the lives of cancer patients by unlocking the potential of precision oncology. Learn more: bayer.com/media/en-us/

#NEWS: Bayer submits a marketing authorization application in Japan for an eye medication with long dosing intervals for the treatment of patients with macular edema following retinal vein occlusion. Learn more: spr.ly/6049FUXth

For Investors & Medical Media. Bayer is proud to be at the 15th European Congress on Menopause and Andropause (European Menopause and Andropause Society (EMAS)) this week. The congress will shine a spotlight on cutting-edge research on health in mid- and later life. #HealthForAll #HungerForNone

+++ #NEWS +++ Bayer to present data from 12 analyses across our cardiovascular portfolio at ESC Heart Failure Congress 2025, showcasing our commitment to heart failure care. Learn more: escardio.org/Congresses-Eve…

#TeamBayer has launched a Phase I trial for a GIRK4 inhibitor targeting atrial fibrillation. This investigational approach aims for rapid cardioversion without sedation, anesthesia or electrical shock, potentially enhancing patient care globally: bayer.com/media/en-us/

#NEWS: Eye medication with long treatment intervals receives approval in China for the treatment of patients with neovascular (wet) age-related macular degeneration. Learn more: spr.ly/6047NJ0xW

For Investors & Medical Media. Bayer is honored to attend ASCO 2025. With the latest breakthroughs in cancer care taking center stage, we’re excited to present new data to improve quality of life for patients at every stage. #TeamBayer #HealthForAll #HungerForNone